Inhibition of retinal neovascularization by gene transfer of small interfering RNA targeting HIF-1α and VEGF

Journal of Cellular Physiology

Volumn 218, Issue 1, 2009, Pages 66-74

  Jiang, Jian ^a   O Bo, X I A ^a   Hui Zhuo, X U ^a   Xiong, Y U ^a   Song, Wei Tao ^a   Xiong, S I Q I ^a   Yan, L I ^a,b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; SMALL INTERFERING RNA; VASCULOTROPIN; HIF1A PROTEIN, HUMAN; MESSENGER RNA; UNCLASSIFIED DRUG; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIUM CELL; GENE THERAPY; GENE TRANSFER; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA NEOVASCULARIZATION; RETINOPATHY; UMBILICAL VEIN; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; CELL CULTURE; DISEASE MODEL; DRUG ANTAGONISM; GENETIC TRANSFECTION; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; NUCLEOTIDE SEQUENCE; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

MUS;

ANIMALS; BASE SEQUENCE; BLOTTING, WESTERN; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOWN-REGULATION; GENE THERAPY; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED C57BL; RETINAL NEOVASCULARIZATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 58149164755     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.21566     Document Type: Article

References (32)

1. Afzal A, Shaw LC, Ljubimov AV, Boulton ME, Segal MS, Grant MB. 2007. Retinal and choroidal microangiopathies: Therapeutic opportunities. Microvasc Res 74:131-144.
2. Ashrafi K, Chang FY, Watts JL, Fraser AG, Kamath RS, Ahringer J, Ruvkun G. 2003. Genome-Wide RNAi analysis of Caenorhabditis elegans fat regulatory genes. Nature 421:268-272.
3. Berns K, Hijmans EM, Mullenders J, Brummelkamp TR, Velds A, Heimerikx M, Kerkhoven RM, Madiredjo M, Nijkamp W, Weigelt B, Agami R, Ge W, Cavet G, Linsley PS, Beijersbergen RL, Bernards R. 2004. A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Natrue 428:431-437.
4. Campochiaro PA, Hackett SF. 2003. Ocular neovascularization: A valuable model system. Oncogene 22:6537-6548.
5. Chen C, Pore N, Behrooz A, Ismail-Beigi F, Maity A. 2001. Regulation of glutl mRNA by hypoxia-inducible factor-l. Interaction between H-ras and hypoxia. J Biol Chem 276:9519-9525.
6. Elbashir SM, Harborth J, Lendeckel W,Yalcin A, Weber K,Tuschl T. 2001. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411:494-498.
7. Fire A,Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. 1998. Potent and specific genetic interference by double-stranded RNAin Caenorhabditis elegans. Nature 391:806-811.
8. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL. 1996. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor l. Mol Cell Biol 16:4604-4613.
9. Frank RN. 2004. Diabetic retinopathy. N Engl J Med 350:48-58.
10. Guan H, Zhou Z, Wang H, Jia SF, Liu W, Kleinerman ES. 2005. A small interfering RNA targeting vascular endothelial growth factor inhibits Ewing's sarcoma growth in a xenograft mouse model. Clin Cancer Res 11:2662-2669.
11. Kim B, Tang Q, Biswas PS, Xu J, Schiffelers RM, Xie FY, Ansari AM, Scaria PV, Woodle MC, Lu P, Rouse BT. 2004. Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes: Therapeutic strategy for herpetic stromal keratitis. Am J Pathol 165:2177-2185.
12. Kolfschoten IG, Van Leenwen B, Berns K, Mullenders J, Beijersbergen RL, Bernards R, Voorhoeve PM, Agami R. 2005. A genetic screen identifies PITXl as a suppressor of RAS activity and tumorigenicity. Cell 121:849-858.
13. Makino Y, Cao R, Svensson K, Bertilsson G, Asman M, Tanaka H, Cao Y, Berkenstam A, Poellinger L. 2001. Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature 414:550-554.
14. Makino Y, Kanopka A, Wilson WJ, Tanaka H, Poellinger L. 2002. Inhibitory PAS domain protein (IPAS) is a hypoxia-inducible splicing variant of the hypoxia-inducible factor-3 alpha locus. J Biol Chem 277:32405-32408.
15. Masuda I, Matsuo T, Yasuda T, Matsuo N. 1996. Gene transfer with liposomes to the intraocular tissues by different routes of administration. Invest Ophthalmol Vis Sci 37:1914-1920.
16. Murata M,Takanami T,Shimizu S, Kubota Y,Horiuchi S, Habano W,Ma JX,Sato S. 2006. Inhibition of ocular angiogenesis by diced small interfering RNAs (siRNAs) specific to vascular endothelial growth factor (VEGF). Curr Eye Res 31:171-180.
17. Ozaki H, Yu AY, Della N, Ozaki K, Luna JD, Yamada H, Hackett SF, Okamoto N, Zack DJ, Semenza GL, Campochiaro PA. 1999. Hypoxia inducible factor-l alpha is increased in ischemic retina: Temporal and spatial correlation with VEGF expression. Invest Ophthalmol Vis Sci 40:182-189.
18. Ozaki H, Seo MS, Ozaki K, Yamada H, Yamada E, Okamoto N, Hofmann F, Wood JM, Campochiaro PA. 2000. Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization. Am J Pathol 156:697-707.
19. Provis JM, Leech J, Diaz CM, Penfold PL, Stone J, Keshet E. 1997. Development of the human retinal vasculature: Cellular relations and VEGF expression. Exp Eye Res 65:555-568.
20. Reich SJ, Fosnot J, Kuroki A, Tang W, Yang X, Maguire AM, Bennett J, Tolentino MJ.2003. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol Vis 9:210-216.
21. Semenza GL. 1999. Regulation of mammalian O2 homeostasis byhypoxia-inducible factor l. Annu RevCell Dev Biol 15:551-578.
22. Semenza GL, Agani F, Booth G, Forsythe J, Iyer N, Jiang BH, Leung S, Roe R, Wiener C, Yu A. 1997. Structural and functional analysis of hypoxia-inducible factor l. Kidney Int 51:553-555.
23. Sen G, Wehrman TS, Myers JW, Blau HM. 2004. Restriction enzyme-generated siRNA (REGS) vectors and libraries. Nat Genet 36:183-189.
24. Shen J, Samul R, Silva RL, Akiyama H, Liu H, Saishin Y, Hackett SF, Zinnen S, Kossen K, Fosnaugh K, Vargeese C, Gomez A, Bouhana K, Aitchison R, Pavco P, Campochiaro PA. 2006a. Suppression of ocular neovascularization with siRNA targeting VEGF receptor l. Gene Ther 13:225-234.
25. Shen J, Yang X, Xiao WH, Hackett SF, Sato Y, Campochiaro PA. 2006b. Vasohibin is up-regulated by VEGF in the retina and suppresses VEGF receptor 2 and retinal neovascularization. FASEB J 20:723-725.
26. Smith LE, Wesolowski E, McLellan A, Kostyk SK, D'Amato R, Sullivan R, D'Amore PA. 1994. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 35:101-110.
27. Stone J, Itin A, Alon T, Pe'er J, Gnessin H, Chan-Ling T, Keshet E. 1995. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J Neurosci 15:4738-4747.
28. Takahashi R, Kobayashi C, Kondo Y, Nakatani Y, Kudo I, Kunimoto M, Imura N, Hara S. 2004. Subcellular localization and regulation of hypoxia-inducible factor-2a in vascular endothelial cells. Biochem Biophys Res Commun 317:84-91.
29. Talks KL, Turley H, Gatter KC, Maxwell PH, Pugh CW, Ratcliffe PJ, Harris AL. 2000. The expression and distribution of the hypoxia-inducible factors HIF-l alpha and HIF-2 alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 157:411-421.
30. Westbrook TF, Martin ES, Schlabach MR, Leng Y, Liang AC, Feng B, Zhao JJ, Roberts TM, Mandel G, Hannon GL, Depinho RA, Chin L, Elledge SJ. 2005. A genetic screen for candidate tumor suppressors identifies REST. Cell 121:837-848.
31. Zamore PD, Tuschl T, Sharp PA, Bartel DP. 2000. RNAi: Double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 101:25-33.
32. Zhang SX, Ma JX. 2007. Ocular neovascularization: Implication of endogenous angiogenic inhibitors and potential therapy. Prog Retin Eye Res 26:1-37.